Evaluation of immune-enhancing effects of ibuprofen in an immunodeficiency model.
Three children and one adult with chronic mucocutaneous candidosis with documented deficient cellular immunity to Candida antigen were evaluated as a model to study the specific cellular immune-enhancing potential of the prostaglandin synthetase inhibitor ibuprofen. Oral ibuprofen failed to have any consistent effect during sequential 4-week on and off cycles on the following parameters: delayed hypersensitivity skin testing; lymphocyte transformation to Candida antigen; T-cell subsets as determined by monoclonal antibody techniques; production of human immune interferon in response to staphylococcal enterotoxin A (SEA). Two patients showed a trend toward enhanced lymphocyte transformation to PHA while taking ibuprofen. In two patients who were studied 8-10 weeks after discontinuation of oral ketoconazole therapy, clinical recurrence of CMC was not prevented by oral ibuprofen therapy.
D002177:Candidiasis / Q000276:immunology*; D002178:Candidiasis, Chronic Mucocutaneous / Q000276:immunology*; D016861:Cyclooxygenase Inhibitors; D006801:Humans; D007052:Ibuprofen / Q000494:pharmacology* / Q000627:therapeutic use; D007111:Immunity, Cellular / Q000187:drug effects*; D007428:Intradermal Tests; D008213:Lymphocyte Activation; D013601:T-Lymphocytes / Q000032:analysis
D016861:Cyclooxygenase Inhibitors; D007052:Ibuprofen